A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
OBJECTIVE: To evaluate semaglutide use among people with HIV (PWH) with medical indications by race and ethnicity. RESEARCH DESIGN AND METHODS: We identified PWH in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort a…
Glucagon-like peptide-1 receptor agonist (GLP1a) agonists are one of the most recent discoveries to improve blood glucose control and provide satiety. The U.S. Food and Drug Administration (FDA) approved the first of these therapeutics for the manage…
Type 2 diabetes and obesity have some overlapping pathophysiology. This has allowed for the creation of therapies which are highly effective in treating both conditions. Weekly subcutaneous incretin agonists are preferred agents as they provide signi…
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) have a strong pathophysiological interrelationship, and their combination worsens prognosis. SUMMARY: This article briefly reviews the bidirectional e…
AIM: This meta-analysis aims to evaluate the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RAs), on new-onset atrial fibrillation (AF) in randomized clinical trials (RCTs). METHODS AND RESULTS: Twenty-six RCTs involving 48,…
Despite considerable advances in the systemic delivery of peptides, their susceptibility to gastrointestinal degradation and high molecular weight, which restricts permeability across biological barriers, remain obstacles to oral administration. As a…
Cardiovascular-Kidney-Metabolic syndrome, introduced by the American Heart Association in 2023, represents a complex and interconnected spectrum of diseases driven by shared pathophysiological mechanisms. However, this framework notably excludes the…
OBJECTIVE: This study aimed to evaluate the weight loss efficacy of semaglutide initiated 6 months after laparoscopic sleeve gastrectomy (LSG). METHODS: This retrospective study included patients undergoing primary LSG. Patients receiving semaglutide…
BACKGROUND AND AIMS: Oral semaglutide and empagliflozin are commonly used for the management of type 2 diabetes (T2D), but head-to-head comparisons in real-world settings are limited. We aimed to emulate the PIONEER-2 trial using electronic health re…
Heart failure (HF) and atherosclerosis represent two major cardiovascular diseases that are intricately linked, both contributing significantly to global morbidity, mortality, and healthcare burden. Despite substantial progress in diagnostic methods…
The onset of type 2 diabetes mellitus (T2DM) in prepubertal age is not uncommon nowadays. Here we are reporting on a young boy who was diagnosed with diabetes at the age of eight years. Diagnosis of diabetes was made based on symptoms of hyperglycemi…
BACKGROUND: Obesity is a chronic medical condition with a rising prevalence in the United States. A wide range of morbidity and mortality is associated with obesity, with coronary artery disease being among the most common. Ischemic heart disease con…
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has transformed the treatment landscape for type 2 diabetes and obesity due to its robust efficacy and wide-ranging therapeutic benefits. This review outlines semaglutide's diverse me…
The European Society of Cardiology annual congress is the premier global platform for dissemination and unraveling major scientific advances in the field of cardiology. Each year a myriad number of scientific ideas are exchanged at this meeting and m…
The development of drugs targeting Nutrient Stimulated Hormone receptors has ushered in a dramatic change in our approach to weight management because of their ability to achieve weight losses of 10%, 20%, even 30% in significant numbers of patients.…